DBVT
DBV Technologies
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Buy"
EPS Beats Expectation
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About DBVT
Dbv Technologies S.A.
A developer of therapeutics based on epicutaneous immunotherapy to treat severe food allergies
Biological Technology
03/29/2002
10/22/2014
NASDAQ Stock Exchange
109
12-31
Depository Receipts (Ordinary Shares)
107 Av. de la République, 92320 Chatillon
--
DBV Technologies S.A. The company was incorporated under the laws of the French Republic on March 29, 2002. The company is a clinical stage specialty biopharmaceutical company focused on transforming the field of immunotherapy by developing a new technology platform called Viaskin. The company's treatment is based on epidermal immunotherapy, or EPIT, its proprietary method of using Viaskin to deliver bioactive compounds to the immune system through intact skin.
Company Financials
EPS
DBVT has released its 2024 Q1 earnings. EPS was reported at -0.28, versus the expected -0.21, missing expectations. The chart below visualizes how DBVT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DBVT has released its 2024 Q4 earnings report, with revenue of 511.00K, reflecting a YoY change of -94.24%, and net profit of -23.02M, showing a YoY change of -105.75%. The Sankey diagram below clearly presents DBVT’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
